Abstract

Cancer therapy using oncolytic virus has shown pre-clinical and clinical efficacy. Here, the authors report ExtraCRAd, an oncolytic virus cloaked with tumour cell membrane and report its therapeutic effects in vitro and in vivo in multiple mouse tumour models.

Details

Title
Artificially cloaked viral nanovaccine for cancer immunotherapy
Author
Fusciello, Manlio 1 ; Fontana, Flavia 2   VIAFID ORCID Logo  ; Tähtinen, Siri 1 ; Capasso, Cristian 1 ; Feola, Sara 1   VIAFID ORCID Logo  ; Martins, Beatriz 1 ; Chiaro, Jacopo 1 ; Peltonen, Karita 1   VIAFID ORCID Logo  ; Ylösmäki, Leena 1 ; Ylösmäki, Erkko 1 ; Hamdan, Firas 1   VIAFID ORCID Logo  ; Kari, Otto K 1 ; Ndika, Joseph 3   VIAFID ORCID Logo  ; Alenius, Harri 4 ; Urtti, Arto 5 ; Hirvonen, Jouni T 2 ; Santos, Hélder A 6   VIAFID ORCID Logo  ; Cerullo, Vincenzo 7   VIAFID ORCID Logo 

1  Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki, Helsinki, Finland 
2  Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland 
3  Systems Toxicology Group, Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland 
4  Systems Toxicology Group, Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 
5  Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland 
6  Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland 
7  Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland; Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University Federico II, Naples, Italy 
Pages
1-13
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41467-019-13744-8
ProQuest document ID
2327905398
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.